Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Sofinnova Telethon Fund
BioCentury | Jun 6, 2023
Deals
June 6 Quick Takes: Alkermes wins arbitration with J&J
Plus: Gurnet Point, Novo taking Paratek private, and updates from Illumina, Sequoia, AAVantgarde, Acepodia and GSK
BioCentury | May 13, 2022
Finance
In latest Italy deal, Sofinnova seeds nanodelivery start-up NanoPhoria with €3.5M
Targeted, non-viral drug delivery start-up is eighth deal for European firm’s Italy-focused Telethon Fund
BioCentury | May 13, 2022
Data Byte
Distillery spotlight on Italian innovation
Opportunities include compounds and targets for cancer, neurology and musculoskeletal diseases, and discoveries from company founders
BioCentury | May 9, 2022
Data Byte
Italian seed and series A financings since 2020
At least 12 Italian start-ups have attracted seed or series A funding since 2020, with Sofinnova and Claris the most active VCs
BioCentury | Apr 29, 2022
Finance
Two years into Telethon Fund, Sofinnova builds Italy portfolio as ecosystem matures
European firm’s Seghezzi: Momentum building for scientific deal flow as region draws funding, teams, infrastructure
BioCentury | Apr 21, 2022
Deals
April 21 Quick Takes: Reify’s big round to support clinical trial diversity
Plus Terran gains rights to two late-stage candidates from Sanofi, and updates from Ampio, Nephris, Jacobus and more
BioCentury | Nov 12, 2021
Finance
Genenta poised to become first Italian biotech to list on NASDAQ
Led by Pierluigi Paracchi, cancer gene therapy company looking to raise up to $34.5M
BioCentury | May 11, 2021
Emerging Company Profile
Genespire: boosting gene therapy efficiency, efficacy
Emerging Company Profile: Milan-based Genespire is developing high-efficiency
BioCentury | Apr 30, 2020
Finance
April 29 Quick Takes: After ADC approval, Immunomedics raises $420M for rollout; plus Genespire, Vertex, Ocumension and Cadent
BioCentury | Apr 20, 2020
Finance
French VC Sofinnova expanding start-up ecosystem in Italy with new local fund’s first investments
VC unveils first investments from new fund launched with Italian charity Fondazione Telethon
Items per page:
1 - 10 of 11